SALT LAKE CITY, Feb. 28, 2018 -- One of the most successful brands in the history of weight-loss supplements, Sensa, is making a comeback as Sensa Clinical. The brand name has been acquired by Voss Laboratories, which adds decades of weight-loss industry product development capabilities and powerful clinical trials to support a 100% new formulation. The new Sensa Clinical blocks up to 350 calories a day‡ and inhibits the release of the hunger hormone ghrelin; a powerful 1-2 punch to the paunch. The revolutionary, clinically validated weight-loss formula works by keeping the body from metabolizing calories. Sensa Clinical retails for $59.99 for a 30-day supply, and primary distribution will launch at www.NewSensa.com.
Sensa Clinical’s new, sleek packaging is filled with a 30-day supply of sachets. When the new Sensa Clinical granulated powder is sprinkled over and eaten with a meal rich in complex carbs, the proprietary formula activates immediately as food hits the stomach.
“Clinical research shows that subjects lost an average of 6.4 pounds in 30 days,” says Dr. Amy Heaton, Ph.D., and Director of Scientific Affairs for Voss. “Taking into account their baseline metabolic characteristics and the 2,000 to 2,200 calorie eating plan they followed, the weight loss achieved equates to an additional 150-350 calories blocked per day. The research also showed that the formula suppresses the hunger hormone ghrelin and had a dramatic effect on satiety. We chose the compounds for this formula based on numerous published clinical trials that have been performed throughout national and international universities and scientific institutions.”
Salt Lake City-based Voss Laboratories is part of the Basic Research family of nutraceutical and cosmeceutical brands, which, since 1993, has developed and distributed over 26 enormously popular brands, each backed by verifiable science. Brands include SeroVital, Zantrex, Growth Factor-9, and the cosmeceutical powerhouse product: StriVectin. "We have extensive knowledge in product development and an excellent scientific talent pool that flawlessly executes the creation of safe, efficacious products that help our customers live the life they really want," said Bodee Gay, CEO of Voss Laboratories.
About: Sensa Clinical is a uniquely delivered weight-loss formula distributed by Salt Lake City-based Voss Laboratories Sensa Clinical works by keeping the body from metabolizing calories and overproducing the hunger hormone ghrelin. A tasteless powder that is sprinkled on food once a day, the newly reformulated Sensa Clinical contains a functional compound that has been clinically validated to block up to 350 calories a day‡. The Sensa Clinical trademark was acquired by Voss Laboratories in 2018.
†Use in conjunction with the simple meal plan provided within the Sensa Clinical packaging. Read the entire label and meal plan before use. Individual results will vary.
‡In a clinical trial of the key compound in Sensa Clinical, subjects lost an average of 6.4 lbs. in only 30 days. Taking into account their baseline metabolic characteristics and the 2,000-2,200-calorie diet plan they followed, the weight loss achieved equates to an additional 150-350 calories blocked per day. While the study subjects achieved their dramatic weight loss without the addition of a prescribed exercise program, adding a sensible exercise regimen to your healthy lifestyle should only enhance your results.
| These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. |
Press contacts:
Sabrina Propper / Alyson Dutch
BROWN + DUTCH PR, INC. 310.456.7151
[email protected], [email protected]


Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Washington Post Publisher Will Lewis Steps Down After Layoffs 



